Immunome IMNM Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunome's accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunome's accrued expenses and other liabilities?
- Immunome (IMNM) reported accrued expenses and other liabilities of $21.88M in Q1 2026.
- How has Immunome's accrued expenses and other liabilities changed year-over-year?
- Immunome's accrued expenses and other liabilities increased by 23.9% year-over-year, from $17.66M to $21.88M.
- What is the long-term trend for Immunome's accrued expenses and other liabilities?
- Over 5 years (2020 to 2025), Immunome's accrued expenses and other liabilities has grown at a 97.9% compound annual growth rate (CAGR), from $1.37M to $41.65M.